DNAPrint genomics CEO Richard Gabriel Interviewed by Wall Street Transcript.
The interview is available free on line at the Transcript's Web site (www.twst.com/ceos.htm).
Mr. Gabriel provides examples of how DNAPrint genomics' DNAWITNESS(TM) forensics technology for the law enforcement market is utilized in crime scene investigations. He also went into detail about the Company's ANCESTRYbyDNA(TM) product for the consumer market, which targets individuals who want to trace their family heritage.
Mr. Gabriel also discussed the Company's recently announced exclusive worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) for a project to develop a new, more potent and longer acting form of the anemia drug Erythropoietin (EPO), which currently has a worldwide market that exceeds $10 billion.
"Our goal is to develop and market a 'Super'-EPO, a more powerful form of the drug," Mr. Gabriel said. "This is a perfect fit within the Company's overarching strategy to utilize recent genomics and chemistry advances made by our researchers to develop next-generation drugs that maximize efficacy and minimize side effects by tailoring medication for specific individuals and well-defined population sectors."
The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800-246-7673.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company's ANCESTRYby DNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit www.dnaprint.com.
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.